Merck.com - Product News

Merck.com - Product News http://www.merck.com/newsroom/news-release-archive/product/ Merck.com - Product News Merck.com - Product News 142 42 http://www.merck.com/newsroom/news-release-archive/product/ http://www.merck.com/site_images/mercklogo-rss.jpg FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience 2/02/2012 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2012_0202.html?src=rss 02-Feb-2012 New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease 1/25/2012 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2012_0125.html?src=rss 25-Jan-2012 FDA Approves Merck’s ISENTRESS® (raltegravir) for Use in Children Ages Two Years and Older as Part of HIV-1 Combination Therapy 1/6/2012 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2012_0106.html?src=rss 6-Jan-2012 Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV 12/21/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1221.html?src=rss 21-Dec-2011 Merck Announces Initiation of Clinical Development Collaboration with Roche To Evaluate Investigational Combination Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Infection 12/15/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1215.html?src=rss 15-Dec-2011 Merck Announces Results of ZOLINZA® (vorinostat) Phase III and IIb Trials for Investigational Use for Multiple Myeloma at American Society of Hematology Annual Meeting 12/12/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1212.html?src=rss 12-Dec-2011 Merck Launches NEXPLANON® (etonogestrel implant) 68 mg in the United States - A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years 11/09/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1109.html?src=rss 09-Nov-2011 Interim Data for Merck's VICTRELIS™ (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting 11/05/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1105.html?src=rss 05-Nov-2011 FDA Advisory Committee Unanimously Recommends Approval of Merck's VYTORIN® (ezetimibe/simvastatin) for Use in Patients with Pre-Dialysis Chronic Kidney Disease 11/02/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1102.html?src=rss 02-Nov-2011 New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males 10/26/2011 http://www.merck.com/newsroom/news-release-archive/vaccine-news/2011_1026.html?src=rss 26-Oct-2011 CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men 10/25/2011 http://www.merck.com/newsroom/news-release-archive/vaccine-news/2011_1025.html?src=rss 25-Oct-2011 Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD) 10/24/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1024.html?src=rss 24-Oct-2011 Interim Phase IIb Data for Merck's VICTRELIS® (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting 10/20/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1020.html?src=rss 20-Oct-2011 Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1 10/13/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1013.html?src=rss 13-Oct-2011 FDA Approves Merck's JUVISYNC™ (sitagliptin and simvastatin) Tablets, a Once-Daily Therapy for Patients with Type 2 Diabetes Who Need to Lower Blood Sugar and Cholesterol, Known Risk Factors for Cardiovascular Disease 10/07/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_1007.html?src=rss 07-Oct-2011 Merck Announces New Data Analyses for VICTRELIS™ (boceprevir) will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting 09/30/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0930.html?src=rss 30-Sep-2011 Study of ZOLINZA® (vorinostat) for Investigational Use for Advanced Malignant Pleural Mesothelioma Did Not Meet Primary Endpoint 09/23/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0923.html?src=rss 23-Sep-2011 Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race 09/19/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0919.html?src=rss 19-Sep-2011 Merck Partners with Susan G. Komen for the Cure® on Historic Initiative to Help Address Cervical and Breast Cancer in Developing Nations 09/13/2011 http://www.merck.com/newsroom/news-release-archive/vaccine-news/2011_0913.html?src=rss 13-Sep-2011 Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV) 08/03/2011 http://www.merck.com/newsroom/news-release-archive/vaccine-news/2011_0803.html?src=rss 18-July-2011 VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the European Union for Treatment of Chronic Hepatitis C 07/18/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0718.html?src=rss 18-July-2011 Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1 07/18/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0718.html?src=rss 18-July-2011 Merck Receives Approval to Market GARDASIL, ZOLINZA and CUBICIN in Japan 07/01/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0701.html?src=rss 01-July-2011 In a New Post-Hoc Analysis Based on the AACE/ACE Diabetes Algorithm Significantly More Patients Achieved Blood Sugar Goals with Initial Therapy with Merck's Diabetes Medicine JANUMET® (sitagliptin/metformin HCl) Compared to Metformin Alone 06/25/2011 http://www.merck.com/newsroom/newsroom/news-release-archive/prescription-medicine-news/2011_0625.html?src=rss 25-June-2011 Merck Statement Regarding FDA Approval of Changes to Trade Packaging Design for Several Medicines from Merck 06/10/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0610.html?src=rss 10-June-2011 U.S. Prescribing Information for Simvastatin Revised to Include New Limits on the Use of the Highest Dose -- 80 mg -- and Updated Drug Interaction Information 06/08/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0608.html?src=rss 08-June-2011 CHMP Issues Positive Opinion for Merck's VICTRELIS™ (boceprevir), Oral Hepatitis C Virus (HCV) Protease Inhibitor 05/20/2011 http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0520.html?src=rss 20-May-2011